SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Körner C.) "

Sökning: WFRF:(Körner C.)

  • Resultat 1-10 av 14
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Jones, Benedict C, et al. (författare)
  • To which world regions does the valence-dominance model of social perception apply?
  • 2021
  • Ingår i: Nature Human Behaviour. - : Springer Science and Business Media LLC. - 2397-3374. ; 5:1, s. 159-169
  • Tidskriftsartikel (refereegranskat)abstract
    • Over the past 10 years, Oosterhof and Todorov's valence-dominance model has emerged as the most prominent account of how people evaluate faces on social dimensions. In this model, two dimensions (valence and dominance) underpin social judgements of faces. Because this model has primarily been developed and tested in Western regions, it is unclear whether these findings apply to other regions. We addressed this question by replicating Oosterhof and Todorov's methodology across 11 world regions, 41 countries and 11,570 participants. When we used Oosterhof and Todorov's original analysis strategy, the valence-dominance model generalized across regions. When we used an alternative methodology to allow for correlated dimensions, we observed much less generalization. Collectively, these results suggest that, while the valence-dominance model generalizes very well across regions when dimensions are forced to be orthogonal, regional differences are revealed when we use different extraction methods and correlate and rotate the dimension reduction solution. PROTOCOL REGISTRATION: The stage 1 protocol for this Registered Report was accepted in principle on 5 November 2018. The protocol, as accepted by the journal, can be found at https://doi.org/10.6084/m9.figshare.7611443.v1 .
  •  
2.
  •  
3.
  •  
4.
  • La Tessa, C., et al. (författare)
  • Out-of-field dose studies with an anthropomorphic phantom : Comparison of X-rays and particle therapy treatments
  • 2012
  • Ingår i: Radiotherapy and Oncology. - : Elsevier BV. - 0167-8140 .- 1879-0887. ; 105:1, s. 133-138
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purpose: Characterization of the out-of-field dose profile following irradiation of the target with a 3D treatment plan delivered with modern techniques. Methods: An anthropomorphic RANDO phantom was irradiated with a treatment plan designed for a simulated 5×2×5cm 3 tumor volume located in the center of the head. The experiment was repeated with all most common radiation treatment types (photons, protons and carbon ions) and delivery techniques (Intensity Modulated Radiation Therapy, passive modulation and spot scanning). The measurements were performed with active diamond detector and passive thermoluminescence (TLD) detectors to investigate the out-of-field dose both inside and outside the phantom. Results: The highest out-of-field dose values both on the surface and inside the phantom were measured during the treatment with 25 MV photons. In the proximity of the Planned Target Volume (PTV), the lowest lateral dose profile was observed for passively modulated protons mainly because of the presence of the collimator in combination with the chosen volume shape. In the far out-of-field region (above 100 mm from the PTV), passively modulated ions were characterized by a less pronounced dose fall-off in comparison with scanned beams. Overall, the treatment with scanned carbon ions delivered the lowest dose outside the target volume. Conclusions: For the selected PTV, the use of the collimator in proton therapy drastically reduced the dose deposited by ions or photons nearby the tumor. Scanning modulation represents the optimal technique for achieving the highest dose reduction far-out-of-field.
  •  
5.
  • Bahadoer, Renu R., et al. (författare)
  • The survival gap between young and older patients after surgical resection for colorectal cancer remains largely based on early mortality : A EURECCA comparison of four European countries
  • 2022
  • Ingår i: Journal of Geriatric Oncology. - : Elsevier. - 1879-4068 .- 1879-4076. ; 13:6, s. 803-812
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: A decade ago, it was demonstrated that the difference in survival between older patients and younger patients with colorectal cancer (CRC) was mainly due to mortality in the first postoperative year. Over the last few years, improvements - especially in perioperative care - have increased survival. The current research investigates whether a survival gap between younger and older patients with CRC still exists on a national level in four European countries.Methods: Population-based data from Belgium, the Netherlands, Norway, and Sweden were collected from patients that underwent surgical resection for primary stage I-III CRC between 2007 and 2016. Relative survival and conditional relative survival (CS), with the condition of surviving the first postoperative year, were calculated for colon and rectal cancer separately, stratified for country and age category (<65, 65–75, ≥75 years). In addition, relative excess risk of death (RER) was estimated, and one-year excess mortality was calculated.Results: Data of 206,024 patients were analyzed. In general, compared to patients <65 years, patients ≥75 years had a worse survival during the first year after surgery, which was most pronounced in Belgium (RER colon cancer 2.5 [95% confidence interval (CI) 2.3–2.8] and RER rectal cancer 2.6 [95% CI 2.3–2.9]). After surviving the first year, CS was mostly not statistically different between patients <65 years and patients ≥75 years with stage I-II, with the exception of stage II colon cancer in Belgium. However, CS remained worse in the largest part of the patients ≥75 years with stage III colon or rectal cancer (except for rectal cancer in Norway).Conclusions: Although differences exist between the countries, the survival gap between young and older patients is based mainly on early mortality and remains only for stage III disease after surviving the first year.
  •  
6.
  • Benatar, Michael, et al. (författare)
  • Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01) : a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
  • 2024
  • Ingår i: Lancet Neurology. - : Elsevier. - 1474-4422 .- 1474-4465. ; 23:7, s. 687-699
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Amyotrophic lateral sclerosis is a progressive neurodegenerative disorder leading to muscle weakness and respiratory failure. Arimoclomol, a heat-shock protein-70 (HSP70) co-inducer, is neuroprotective in animal models of amyotrophic lateral sclerosis, with multiple mechanisms of action, including clearance of protein aggregates, a pathological hallmark of sporadic and familial amyotrophic lateral sclerosis. We aimed to evaluate the safety and efficacy of arimoclomol in patients with amyotrophic lateral sclerosis.Methods: ORARIALS-01 was a multinational, randomised, double-blind, placebo-controlled, parallel-group trial done at 29 centres in 12 countries in Europe and North America. Patients were eligible if they were aged 18 years or older and met El Escorial criteria for clinically possible, probable, probable laboratory-supported, definite, or familial amyotrophic lateral sclerosis; had an ALS Functional Rating Scale-Revised score of 35 or more; and had slow vital capacity at 70% or more of the value predicted on the basis of the participant's age, height, and sex. Patients were randomly assigned (2:1) in blocks of 6, stratified by use of a stable dose of riluzole or no riluzole use, to receive oral arimoclomol citrate 1200 mg/day (400 mg three times per day) or placebo. The Randomisation sequence was computer generated centrally. Investigators, study personnel, and study participants were masked to treatment allocation. The primary outcome was the Combined Assessment of Function and Survival (CAFS) rank score over 76 weeks of treatment. The primary outcome and safety were analysed in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03491462, and is completed.Findings: Between July 31, 2018, and July 17, 2019, 287 patients were screened, 245 of whom were enrolled in the trial and randomly assigned. The modified intention-to-treat population comprised 239 patients (160 in the arimoclomol group and 79 in the placebo group): 151 (63%) were male and 88 (37%) were female; mean age was 57·6 years (SD 10·9). CAFS score over 76 weeks did not differ between groups (mean 0·51 [SD 0·29] in the arimoclomol group vs 0·49 [0·28] in the placebo group; p=0·62). Cliff's delta comparing the two groups was 0·039 (95% CI –0·116 to 0·194). Proportions of participants who died were similar between the treatment groups: 29 (18%) of 160 patients in the arimoclomol group and 18 (23%) of 79 patients in the placebo group. Most deaths were due to disease progression. The most common adverse events were gastrointestinal. Adverse events were more often deemed treatment-related in the arimoclomol group (104 [65%]) than in the placebo group (41 [52%]) and more often led to treatment discontinuation in the arimoclomol group (26 [16%]) than in the placebo group (four [5%]).Interpretation: Arimoclomol did not improve efficacy outcomes compared with placebo. Although available biomarker data are insufficient to preclude future strategies that target the HSP response, safety data suggest that a higher dose of arimoclomol would not have been tolerated.Funding: Orphazyme.
  •  
7.
  • Demichev, Vadim, et al. (författare)
  • A time-resolved proteomic and prognostic map of COVID-19
  • 2021
  • Ingår i: Cell Systems. - : Elsevier BV. - 2405-4712 .- 2405-4720. ; 12:8, s. 780-794.e7
  • Tidskriftsartikel (refereegranskat)abstract
    • COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. We characterized the time-dependent progression of the disease in 139 COVID-19 inpatients by measuring 86 accredited diagnostic parameters, such as blood cell counts and enzyme activities, as well as untargeted plasma proteomes at 687 sampling points. We report an initial spike in a systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution, and immunomodulation. We identify prognostic marker signatures for devising risk-adapted treatment strategies and use machine learning to classify therapeutic needs. We show that the machine learning models based on the proteome are transferable to an independent cohort. Our study presents a map linking routinely used clinical diagnostic parameters to plasma proteomes and their dynamics in an infectious disease.
  •  
8.
  • Goddek, S., et al. (författare)
  • Nutrient mineralization and organic matter reduction performance of RAS-based sludge in sequential UASB-EGSB reactors
  • 2018
  • Ingår i: Aquacultural Engineering. - : Elsevier BV. - 0144-8609 .- 1873-5614. ; 83, s. 10-19
  • Tidskriftsartikel (refereegranskat)abstract
    • There is a recognized need for mineralizing aquaculture-derived sludge in aquaponics systems in order to reduce waste production. Many recent studies of aquacultural waste treatment have focused only the production of biogas as opposed to the potential for mineralization of nutrient-rich sludge. Upflow anaerobic sludge blanket (UASB) reactors provide one possible solution for breaking down sludge into bioavailable nutrients that can subsequently be delivered to plants. As such, this study examines the mineralization performance of sequential UASB reactors that are designed with an expanded granular sludge bed (EGSB) and compared to standard aerobic and anaerobic batch reactors. Results of our experiments demonstrate that only chemical oxygen demand reduction is significantly different. An unexpected drop in pH of one of the three reactor systems revealed that a pH below 6 was able to significantly increase the mineralization and mobilization of nutrients. Approximately 25% of phosphorus, potassium, and calcium could also be recovered from the sludge under lower pH conditions, as compared to the mineralization performance of standard UASB reactors running at a higher pH. However, the opposite effect was observed with respect to organic sludge reduction, where diminished performance was observed in the low-pH reactor. The current study implies that anaerobic reactors operating at low pH can potentially contribute towards improved nutrient recovery in multi-loop aquaponics systems and reduction of additive agents for pH control of the hydroponic subsystem. © 2018 Elsevier B.V.
  •  
9.
  • Horikoshi, Momoko, et al. (författare)
  • New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism.
  • 2013
  • Ingår i: Nature Genetics. - : Springer Science and Business Media LLC. - 1061-4036 .- 1546-1718. ; 45:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Birth weight within the normal range is associated with a variety of adult-onset diseases, but the mechanisms behind these associations are poorly understood. Previous genome-wide association studies of birth weight identified a variant in the ADCY5 gene associated both with birth weight and type 2 diabetes and a second variant, near CCNL1, with no obvious link to adult traits. In an expanded genome-wide association meta-analysis and follow-up study of birth weight (of up to 69,308 individuals of European descent from 43 studies), we have now extended the number of loci associated at genome-wide significance to 7, accounting for a similar proportion of variance as maternal smoking. Five of the loci are known to be associated with other phenotypes: ADCY5 and CDKAL1 with type 2 diabetes, ADRB1 with adult blood pressure and HMGA2 and LCORL with adult height. Our findings highlight genetic links between fetal growth and postnatal growth and metabolism.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 14
Typ av publikation
tidskriftsartikel (14)
Typ av innehåll
refereegranskat (14)
Författare/redaktör
Koppelman, Gerard H. (3)
Melbye, Mads (3)
McCarthy, Mark I (3)
Boomsma, Dorret I. (3)
Hakonarson, Hakon (3)
Rivadeneira, Fernand ... (3)
visa fler...
Uitterlinden, André ... (3)
Pennell, Craig E (3)
Timpson, Nicholas J. (3)
Ntalla, Ioanna (3)
Horikoshi, Momoko (3)
Geller, Frank (3)
Bradfield, Jonathan ... (3)
Sebert, Sylvain (3)
Bisgaard, Hans (3)
Jacobsson, Bo, 1960 (2)
Raitakari, Olli T (2)
Heinrich, Joachim (2)
Sunyer, Jordi (2)
Davey Smith, George (2)
Estivill, Xavier (2)
Pedersen, Oluf (2)
Hansen, Torben (2)
van Duijn, Cornelia ... (2)
Lehtimäki, Terho (2)
Buxton, Jessica L. (2)
Jarvelin, Marjo-Riit ... (2)
Hattersley, Andrew T (2)
Mahajan, Anubha (2)
Froguel, Philippe (2)
Eriksson, Johan G. (2)
Evans, David M (2)
Hofman, Albert (2)
Postma, Dirkje S (2)
Ring, Susan M (2)
Warrington, Nicole M (2)
Holloway, John W (2)
Hirschhorn, Joel N. (2)
Zeggini, Eleftheria (2)
Lyytikäinen, Leo-Pek ... (2)
Hottenga, Jouke-Jan (2)
Guxens, Monica (2)
Newnham, John P. (2)
St Pourcain, Beate (2)
Dedoussis, George V. (2)
Kreiner-Møller, Eski ... (2)
Barton, Sheila J (2)
Hocher, Berthold (2)
Frayling, Timothy M (2)
Hyppönen, Elina (2)
visa färre...
Lärosäte
Karolinska Institutet (5)
Göteborgs universitet (4)
Umeå universitet (3)
Uppsala universitet (2)
Stockholms universitet (2)
Lunds universitet (2)
visa fler...
Kungliga Tekniska Högskolan (1)
Högskolan Väst (1)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (14)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (6)
Naturvetenskap (3)
Samhällsvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy